Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06990269 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
A Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by ADARx Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 17
- Study locations
NCT06990269: Recruiting Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by ADARx Pharmaceuticals.
NCT06990269 is a Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration that is actively recruiting participants, run by ADARx Pharmaceuticals. The registered enrollment target is 240 participants, above the 166-participant average among 4 other Geographic Atrophy Secondary to Age-related Macular Degeneration trials with a reported enrollment target (45% higher). The trial reports 17 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06990269, a Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, is actively recruiting participants, sponsored by ADARx Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 17
- Study locations
Study Summary
Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Primary Outcome
Rate of change in the area of total EZ loss in the study eye from baseline to Month 12
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ADX-038
Study Locations (17)
Texas
- ADARx Clinical Site - McAllen
- ADARx Clinical Site - Round Rock
- ADARx Clinical Site - San Antonio
- ADARx Clinical Site - The Woodlands
California
- ADARx Clinical Site - Beverly Hills
- ADARx Clinical Site - Huntington Beach
- ADARx Clinical Site - Poway
Arizona
- ADARx Clinical Site - Gilbert
- ADARx Clinical Site - Phoenix
New South Wales
- ADARx Clinical Site - Albury
- ADARx Clinical Site - Parramatta
Ontario
- ADARx Clinical Site - Ottawa
- ADARx Clinical Site - Toronto
Florida
- ADARx Clinical Site - Orlando
Maryland
- ADARx Clinical Site - Hagerstown
Pennsylvania
- ADARx Clinical Site - Erie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-11-10 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What NCT06990269 shows while recruiting
NCT06990269 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 166-participant average among 4 other Geographic Atrophy Secondary to Age-related Macular Degeneration trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Geographic Atrophy Secondary to Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06990269 lists 17 locations in 9 states (Texas, California, Arizona).
Frequently Asked Questions
What is clinical trial NCT06990269 about?
NCT06990269 is a clinical study titled "Phase 2 Study of ADX-038 in Participants With Geographic Atrophy". Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
What is the current status of trial NCT06990269?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-11-10. Estimated completion is 2027-12.
What conditions does trial NCT06990269 study?
This clinical trial studies the following conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration.
What interventions are being tested in trial NCT06990269?
The interventions under investigation include: Placebo (DRUG), ADX-038 (DRUG).
Who is sponsoring clinical trial NCT06990269?
This trial is sponsored by ADARx Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06990269 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Maryland, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy Secondary to Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
RECRUITING · Phase 2
-
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
RECRUITING · Phase 1
-
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI